“Pragmatic trials” are the new buzz in clinical research. I want to spend this post talking a bit about why—and the reasons for NCCAM’s particular interest in this topic.
Past Blog Posts
On September 9, NCCAM was pleased to host Patricia Hibberd, M.D., Ph.D., who delivered a lecture at NIH on “Probiotics, the Microbiome, and Host Immune Response: Insights for Novel Therapeutic Approaches.” Dr. Hibberd is professor of pediatrics at Harvard Medical School, and chief of the Division of Global Health at Massachusetts General Hospital for Children, as well as professor of global health at Harvard School of Public Health.
Earlier this week, a new secondary analysis of results of the Trial to Assess Chelation Therapy (TACT) was published in the journal Circulation: Cardiovascular Quality & Outcomes and presented at the American Heart Association meeting. The analysis suggests that the EDTA-based chelation treatments produced a marked reduction in cardiovascular events and death in participants with diabetes. Furthermore, the results suggest that treatments had no benefit in those who did not have diabetes.
Chronic low-back pain is one of the most common and costly health complaints. It can be debilitating, and it remains a tough condition to diagnose, treat, and study. Spinal manipulative therapy is often used to treat a large portion of low-back pain in the United States, and is included in current clinical practice guidelines for treatment of this condition. Yet, recommendations for duration and frequency vary widely and there is no consensus on its efficacy.